 Proto-Oncogene Proteins c-myc
"Proto-Oncogene Proteins c-myc" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cellular DNA-binding proteins encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.
| Descriptor ID |
D016271
|
| MeSH Number(s) |
D12.776.260.676 D12.776.624.664.700.189 D12.776.660.765
|
| Concept/Terms |
Proto-Oncogene Proteins c-myc- Proto-Oncogene Proteins c-myc
- Proto Oncogene Proteins c myc
- myc Proto-Oncogene Product p62
- myc Proto Oncogene Product p62
- myc Proto-Oncogene Proteins
- Proto-Oncogene Proteins, myc
- myc Proto Oncogene Proteins
- p62(c-myc)
- Proto-Oncogene Products c-myc
- Proto Oncogene Products c myc
- Proto-Oncogene Proteins myc
- Proteins myc, Proto-Oncogene
- Proto Oncogene Proteins myc
- myc, Proto-Oncogene Proteins
- c-myc Proteins
- c myc Proteins
- p62 c-myc
- p62 c myc
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-myc".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-myc".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-myc" by people in UAMS Profiles by year, and whether "Proto-Oncogene Proteins c-myc" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2021 | 2 | 0 | 2 | | 2020 | 0 | 1 | 1 | | 2019 | 0 | 2 | 2 | | 2017 | 1 | 2 | 3 | | 2016 | 0 | 2 | 2 | | 2015 | 2 | 1 | 3 | | 2014 | 2 | 2 | 4 | | 2013 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2003 | 2 | 2 | 4 | | 1999 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1992 | 3 | 0 | 3 | | 1991 | 1 | 0 | 1 | | 1989 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-myc" by people in Profiles over the past ten years.
-
Maura F, Coffey DG, Stein CK, Braggio E, Ziccheddu B, Sharik ME, Du MT, Tafoya Alvarado Y, Shi CX, Zhu YX, Meermeier EW, Morgan GJ, Landgren O, Bergsagel PL, Chesi M. The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans. Nat Commun. 2024 May 07; 15(1):3844.
-
George J, Li Y, Kadamberi IP, Parashar D, Tsaih SW, Gupta P, Geethadevi A, Chen C, Ghosh C, Sun Y, Mittal S, Ramchandran R, Rui H, Lopez-Berestein G, Rodriguez-Aguayo C, Leone G, Rader JS, Sood AK, Dey M, Pradeep S, Chaluvally-Raghavan P. RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Rep. 2021 11 02; 37(5):109934.
-
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Ciampricotti M, Chow A, Offin M, Ray-Kirton J, Egger JD, Bhanot UK, Linkov I, Asher M, Roehrl MH, Ventura K, Qiu J, de Stanchina E, Chang JC, Rekhtman N, Houck-Loomis B, Koche RP, Yu HA, Sen T, Rudin CM. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. J Hematol Oncol. 2021 10 16; 14(1):170.
-
Ryan KR, Giles F, Morgan GJ. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. Eur J Haematol. 2021 Jan; 106(1):90-99.
-
Figueiredo VC, Englund DA, Vechetti IJ, Alimov A, Peterson CA, McCarthy JJ. Phosphorylation of eukaryotic initiation factor 4E is dispensable for skeletal muscle hypertrophy. Am J Physiol Cell Physiol. 2019 12 01; 317(6):C1247-C1255.
-
Wang H, Diaz AK, Shaw TI, Li Y, Niu M, Cho JH, Paugh BS, Zhang Y, Sifford J, Bai B, Wu Z, Tan H, Zhou S, Hover LD, Tillman HS, Shirinifard A, Thiagarajan S, Sablauer A, Pagala V, High AA, Wang X, Li C, Baker SJ, Peng J. Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes. Nat Commun. 2019 08 16; 10(1):3718.
-
Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer. 2018 01; 118(1):52-61.
-
Kendrick S, Muranyi A, Gokhale V, Hurley LH, Rimsza LM. Simultaneous Drug Targeting of the Promoter MYC G-Quadruplex and BCL2 i-Motif in Diffuse Large B-Cell Lymphoma Delays Tumor Growth. J Med Chem. 2017 08 10; 60(15):6587-6597.
-
Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F. NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. J Hematol Oncol. 2017 01 13; 10(1):17.
-
Li N, Johnson DC, Weinhold N, Studd JB, Orlando G, Mirabella F, Mitchell JS, Meissner T, Kaiser M, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression. Nat Commun. 2016 11 24; 7:13656.
-
Iden M, Fye S, Li K, Chowdhury T, Ramchandran R, Rader JS. The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis. PLoS One. 2016; 11(5):e0156274.
-
Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016 Mar; 101(3):e116-9.
-
Kendrick S, Tus K, Wright G, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Braziel RM, Ott G, Delabie J, Cook JR, Weisenburger DD, Greiner TC, Fu K, Staudt LM, Gascoyne RD, Scott DW, Rimsza LM. Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leuk Lymphoma. 2016; 57(3):717-20.
-
Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015 Apr 23; 6:6997.
-
Willett RA, Kudlyk TA, Lupashin VV. Expression of functional Myc-tagged conserved oligomeric Golgi (COG) subcomplexes in mammalian cells. Methods Mol Biol. 2015; 1270:167-77.
-
Weinhold N, Meissner T, Johnson DC, Seckinger A, Moreaux J, F?rsti A, Chen B, Nickel J, Chubb D, Rawstron AC, Doughty C, Dahir NB, Begum DB, Young K, Walker BA, Hoffmann P, N?then MM, Davies FE, Klein B, Goldschmidt H, Morgan GJ, Houlston RS, Hose D, Hemminki K. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells. Haematologica. 2015 Mar; 100(3):e110-3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|